Mortality is higher with drug eluting stents than with uncoated stents, studies find

Drug-eluting stents: more dollars than sense?

All drug-eluting stents are equal, but some drug-eluting stents are more equal than others.

b t r t a s S g S d s b r a p a T v v p he first battle fought by drug-eluting stents (DES) was ith bare-metal stents. The 2 DES approved by the U.S. ood and Drug Administration, sirolimus drug-eluting tents (S-DES) and paclitaxel drug-eluting stents (P-DES), howed superiority in significantly reducing restenosis rates nd target lesion revascularization rates compared with are-metal stents in a...

Meta-analysis comparing drug-eluting stents with bare metal stents.

We performed a meta-analysis of 10 randomized trials of 5,066 patients with 6 to 12 months of follow-up. The summary risk differences excluded any major differences between the 2 types of stents for death (0.12%, 95% confidence interval [CI] -0.34% to 0.58%, p = 0.60) and overall myocardial infarction (0.04%, 95% CI -0.72% to 0.81%, p = 0.91). There was a modest increase in the risk of Q-wave m...

Drug-Eluting Stents in Preclinical Studies

The arrival of drug-eluting stents raises important questions about preclinical evaluation of devices and the optimal means of predicting clinical safety and efficacy. The Interventional, Regulatory, Commercial, and Scientific communities have all asked for assistance in defining criteria for device evaluation. This document is an integrated view of requirements for evaluating drug-eluting sten...

Survival Benefit With Drug-Eluting Stents in Observational Studies

Background—Recently, there has been increased interest in leveraging observational studies for comparative effectiveness research. Without robust and valid risk adjustment, however, findings from these nonrandomized studies may remain biased. Previous studies examining long-term mortality with drug-eluting stents (DESs) have demonstrated discordant results between randomized trials and observat...